SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis
Monday, May 10th, 2010 Posted in prostate cancer | No Comments »A new study at McGill University Health Centre, Montreal, Quebec, Canada, examined the efficacy of a Src/Abl kinase inhibitor SKI-606 (Bosutinib) for its effect on prostate cancer growth and skeletal metastasis. Treatment of highly invasive human prostate cancer cells PC-3 ...
SEP15 genetic variation and prostate cancer risk
Sunday, May 9th, 2010 Posted in prostate cancer risks | No Comments »The role of selenium in prostate cancer (PCa) risk remains controversial, but many epidemiologic studies suggest an inverse association with more aggressive disease. A recently discovered selenoprotein, SEP15, which is highly expressed in the prostate, may play a role either ...
Prostate cancer patients on statins have better outcomes after radiotherapy
Saturday, May 8th, 2010 Posted in radiation therapy | No Comments »There is a large collection of evidence to suggest that men who are on long-term statin therapy (with drugs like simvastatin, atorvastatin/Lipitor, or rosuvastatin/Crestor) are at lower risk for prostate cancer and do better than average in terms of treatment ...
New strategies in prostate cancer
Friday, May 7th, 2010 Posted in prostate cancer | No Comments »Whereas the role of Metabolic Syndrome (MS), and a high fat diet in prostate cancer (PCa) risk is still a matter of intense debate, it is becoming increasingly clear that obesity can cause perturbations in metabolic pathways that contribute to ...
New prostate cancer treatment offers fewer side effects
Wednesday, May 5th, 2010 Posted in hifu | No Comments »For many men, treatment for prostate cancer often leaves them experiencing impotence and incontinence, but a new procedure available outside the United States is producing the same results without the side effects. It seems that a new treatment called High Intensity ...
PSA kinetics do not predict pathology in men on active surveillance
Tuesday, May 4th, 2010 Posted in watchful waiting | No Comments »A new study at Johns Hopkins University School of Medicine aimed to assess the predictive ability of prostate-specific antigen (PSA) velocity (PSAV) and doubling time (PSADT) for biopsy progression and adverse pathology at prostatectomy among men with low-risk prostate cancer ...
FDA probes diabetes risk with prostate cancer meds
Monday, May 3rd, 2010 Posted in prostate cancer | No Comments »FDA Conducting Safety Review of Commonly Used Prostate Cancer DrugsPreliminary review suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with Gonadotropin-Releasing Hormone (GnRH) agonists. (GnRH) agonists, a class of medications primarily used to treat ...
Clinicians should monitor serum testosterone levels
Sunday, May 2nd, 2010 Posted in prostate cancer risks | No Comments »A study that will be published in next issue of European Urology recommends strongly that clinicians should monitor serum testosterone (known as serum T) levels during androgen-deprivation therapy (ADT) in men with prostate cancer. While there are few data to show ...
Robotic versus open radical prostatectomy
Saturday, May 1st, 2010 Posted in prostatectomy | No Comments »A research team at Kansas University Medical Center, Kansas City, Kansas, surveyed urologists from the central United States to determine possible surgeon factors for the popularity of the robotic assisted radical prostatectomy (RARP). Conclusions suggest the robotic assisted radical prostate ...